A comparison of symptoms and drug use between patients with methamphetamine associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric wards

Psychiatry Research

Volumn 206, Issue 1, 2013, Pages 17-21

  Medhus, Sigrid ^a,b   Mordal, Jon ^a,b   Holm, Bjørn ^a   Mørland, Jørg ^b,c   Bramness, Jørgen G ^b,c  

^a LOVISENBERG DIAKONALE HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Drugs of dependence disorders; Inpatient treatment; Psychotic disorders

Indexed keywords

METHAMPHETAMINE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DELUSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; DRUG USE; EDUCATIONAL STATUS; EMPLOYMENT STATUS; FEMALE; HALLUCINATION; HOSTILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METHAMPHETAMINE DEPENDENCE; MULTIPLE DRUG ABUSE; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; RESIDUAL SCHIZOPHRENIA; SCHIZOPHRENIA; SYMPTOM;

ADULT; AMPHETAMINE-RELATED DISORDERS; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; METHAMPHETAMINE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84875400497     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.09.023     Document Type: Article

References (41)

1. Angrist B., Sathananthan G., Wilk S., Gershon S. Amphetamine psychosis: behavioral and biochemical aspects. Journal of Psychiatric Research 1974, 11:13-23.
2. Angrist B.M., Gershon S. The phenomenology of experimentally induced psychosis-preliminary observations. Biological Psychiatry 1970, 2:95-107.
3. Batki S.L., Harris D.S. Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia. American Journal on Addictions 2004, 13:461-470.
4. Bell D.S. Comparison of amphetamine psychosis and schizophrenia. British Journal of Psychiatry 1965, 111:701-707.
5. Bell The experimental reproduction of amphetamine psychosis. Archives of General Psychiatry 1973, 29:35-40.
6. Bogstrand S.T., Normann P.T., Rossow I., Larsen M., Morland J., Ekeberg O. Prevalence of alcohol and other substances of abuse among injured patients in a Norwegian emergency department. Drug and Alcohol Dependence 2011, 117:132-138.
7. Caton C.L., Drake R.E., Hasin D.S., Dominguez B., Shrout P.E., Samet S., Schanzer B. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Archives of General Psychiatry 2005, 62:137-145.
8. Caton C.L., Hasin D.S., Shrout P.E., Drake R.E., Dominguez B., First M.B., Samet S., Schanzer B. Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. British Journal of Psychiatry 2007, 190:105-111.
9. Chen C.K., Lin S.K., Sham P.C., Ball D., Loh E.W., Hsiao C.C., Chiang Y.L., Ree S.C., Lee C.H., Murray R.M. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychological Medicine 2003, 33:1407-1414.
10. Chen C.K., Lin S.K., Sham P.C., Ball D., Loh el W., Murray R.M. Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2005, 136B:87-91.
11. Christophersen A.S., Morland J. Drugged driving, a review based on the experience in Norway. Drug and Alcohol Dependence 1997, 47:125-135.
12. Degenhardt L., Roxburgh A., Black E., Bruno R., Campbell G., Kinner S., Fetherston J. The epidemiology of methamphetamine use and harm in Australia. Drug and Alcohol Review 2008, 27:243-252.
13. Drake R.E., Mueser K.T., Brunette M.F., McHugo G.J. A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatric Rehabilitation Journal 2004, 27:360-374.
14. Ellinwood E.H. Amphetamine psychosis: I. Description of the individuals and process. Journal of Nervous and Mental Disease 1967, 144:273-283.
15. European Monitoring Center for Drugs and Drug Addiction (EMCDDA), 2009. Metamphetamine. A European Union perspective in the global context.
16. Flesland L., Carlsen S. Føre var. Rustrender i Bergen 2010, Stiftelsen Bergenklinikkene, Bergen.
17. Gray S.D., Fatovich D.M., McCoubrie D.L., Daly F.F. Amphetamine-related presentations to an inner-city tertiary emergency department: a prospective evaluation. Medical Journal of Australia 2007, 186:336-339.
18. Grelotti D.J., Kanayama G., Pope H.G. Remission of persistent methamphetamine-induced psychosis after electroconvulsive therapy: presentation of a case and review of the literature. American Journal of Psychiatry 2010, 167:17-23.
19. Griffith J.J., Oates J., Cavanough J. Paranoid Episodes Induced by Drugs 1968, The Journal of the American Medical Association, p. 39. 205 ed.
20. Hall W., Hando J., Darke S., Ross J. Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction 1996, 91:81-87.
21. Harris D., Batki S.L. Stimulant psychosis: symptom profile and acute clinical course. American Journal on Addictions 2000, 9:28-37.
22. Kay S.R., Fiszbein A., Opler L.A. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
23. Kripos (National Crime Investigation Service), 2012. Narkotika-og dopingstatistikk 2011 (Narcotics and doping statistics 2011).
24. Kittirattanapaiboon P., Mahatnirunkul S., Booncharoen H., Thummawomg P., Dumrongchai U., Chutha W. Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug and Alcohol Review 2010, 29:456-461.
25. Latt N., Jurd S., Tennant C., Lewis J., Macken L., Joseph A., Grochulski A., Long L. Alcohol and substance use by patients with psychosis presenting to an emergency department: changing patterns. Australasian Psychiatry 2011, 19:354-359.
26. Leamon M.H., Flower K., Salo R.E., Nordahl T.E., Kranzler H.R., Galloway G.P. Methamphetamine and paranoia: the methamphetamine experience questionnaire. American Journal on Addictions 2010, 19:155-168.
27. Maxwell J.C., Rutkowski B.A. The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007. Drug and Alcohol Review 2008, 27:229-235.
28. McGregor C., Srisurapanont M., Jittiwutikarn J., Laobhripatr S., Wongtan T., White J.M. The nature, time course and severity of methamphetamine withdrawal. Addiction 2005, 100:1320-1329.
29. McKetin R., Hickey K., Devlin K., Lawrence K. The risk of psychotic symptoms associated with recreational methamphetamine use. Drug and Alcohol Review 2010, 29:358-363.
30. McKetin R., Kozel N., Douglas J., Ali R., Vicknasingam B., Lund J., Li J.H. The rise of methamphetamine in Southeast and East Asia. Drug and Alcohol Review 2008, 27:220-228.
31. Mordal J., Bramness J.G., Holm B., Morland J. Drugs of abuse among acute psychiatric and medical admissions: laboratory based identification of prevalence and drug influence. General Hospital Psychiatry 2008, 30:55-60.
32. Mordal J., Gundersen O., Bramness J.G. Norwegian version of the Mini-International Neuropsychiatric Interview: feasibility, acceptability and test-retest reliability in an acute psychiatric ward. European Psychiatry 2010, 25:172-177.
33. Parry C.D., Myers B., Pluddemann A. Drug policy for methamphetamine use urgently needed. South African Medical Journal 2004, 94:964-965.
34. Pasic J., Russo J.E., Ries R.K., Roy-Byrne P.P. Methamphetamine users in the psychiatric emergency services: a case-control study. American Journal of Drug and Alcohol Abuse 2007, 33:675-686.
35. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998, 59(Suppl. 20):22-33.
36. Srisurapanont M., Ali R., Marsden J., Sunga A., Wada K., Monteiro M. Psychotic symptoms in methamphetamine psychotic in-patients. International Journal of Neuropsychopharmachology 2003, 6:347-352.
37. Srisurapanont M., Arunpongpaisal S., Wada K., Marsden J., Ali R., Kongsakon R. Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 35:959-964.
38. Ujike H., Katsu T., Okahisa Y., Takaki M., Kodama M., Inada T., Uchimura N., Yamada M., Iwata N., Sora I., Iyo M., Ozaki N., Kuroda S. Genetic variants of D2 but not D3 or D4 dopamine receptor gene are associated with rapid onset and poor prognosis of methamphetamine psychosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2009, 33:625-629.
39. Weaver T., Madden P., Charles V., Stimson G., Renton A., Tyrer P., Barnes T., Bench C., Middleton H., Wright N., Paterson S., Shanahan W., Seivewright N., Ford C. Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. British Journal of Psychiatry 2003, 183:304-313.
40. World Health Organization, 1993. The ICD-10 Classification of Mental and Behavioral Disorders. Diagnostic Criteria For Research. Geneva.
41. Yeh H.S., Lee Y.C., Sun H.J., Wan S.R. Six months follow-up of patients with methamphetamine psychosis. Zhonghua Yi.Xue.Za Zhi. Chinese Medical Journal (Taipei) 2001, 64:388-394.